For muscle invasive bladder cancer, after neoadjuvant chemotherapy with cis/gem and surgery with residual tumor and lymph node involvement, would you consider adjuvant avelumab as an extrapolation base on the JAVELIN 100 results?

I would not use adjuvant avelumab following radical cystectomy finding residual high risk disease after neoadjuvant chemotherapy. Biologically, this group has disease resistant to neoadjuvant chemotherapy, and is not akin to those with stable or responding disease following platinum therapy included...

Adjuvant (post-op) setting with NED is very different than switch maintenance strategy after induction chemotherapy in the 1L setting. IMvigor010 did not meet the primary endpoint of DFS but we are awaiting (Checkmate 274, Ambassador, and Proof 302) adjuvant trials. I would not use IO in the adjuvan...